Matthew Calistri | Biogen, Inc. |
Michel Vounatsos | Biogen, Inc. |
Michael D. Ehlers, M.D., Ph.D. | Biogen, Inc. |
Alfred W. Sandrock, Jr., M.D., Ph.D. | Biogen, Inc. |
Paul McKenzie | Biogen, Inc. |
Umer Raffat | Evercore Group LLC |
Geoffrey Meacham | Barclays Capital, Inc. |
Eric Schmidt | Cowen and Co. LLC |
Ying Huang | Bank of America Merrill Lynch |
Cory W. Kasimov | JPMorgan Securities LLC |
Geoffrey C. Porges | Leerink Partners LLC |
Carter Gould | UBS Securities LLC |
Matthew K. Harrison | Morgan Stanley & Co. LLC |
Terence Flynn | Goldman Sachs & Co. LLC |
Aharon Gal | Sanford C. Bernstein & Co. LLC |
Michael J. Yee | Jefferies LLC |
Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen third quarter 2017 financial results and business update. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session.